Cellular immunology
Cure8 research brief
Why This Matters
This study points to a plant-derived compound (Astragalus polysaccharides) that reduced colitis severity in a rat model by interfering with HMGB1/TLR4-driven neutrophil extracellular trap formation—pathways implicated in UC inflammation.
It may interest people watching early-stage research on new anti-inflammatory approaches for IBD.
Who Should Pay Attention
Researchers studying immune pathways, NETs, HMGB1/TLR4 signaling, and drug-discovery; clinicians and patients interested in emerging preclinical work on botanicals as potential anti-inflammatory agents.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This abstract reports a preclinical (rat) study testing Astragalus polysaccharides (APS) in a chemical model of severe colitis.
The investigators found that APS reduced disease activity and markers they associate with neutrophil extracellular trap (NET) formation, and that APS appeared to suppress HMGB1/TLR4 signaling and partially restore antioxidant enzyme activity in colon tissue.
The study used TNBS-induced colitis in rats, compared multiple APS doses with DNase I (which degrades NETs), and included an "APS + exogenous HMGB1" rescue experiment that reduced the protective effect of APS.
These results suggest APS can affect inflammatory pathways linked to HMGB1, TLR4, and NETosis in this animal model, but direct evidence at the neutrophil level and translation to humans were not provided in the abstract.
If you follow research on botanicals or mechanisms of NET-associated inflammation, this provides preclinical support for further study rather than clinical evidence.
Keep In Mind
This is an animal (rat) study described in an abstract; it does not provide clinical trial data or direct evidence of safety or efficacy in humans. The authors note that neutrophil-level experiments and translational validation are still needed. Do not interpret this as medical advice or proof that APS is effective or safe in people with UC.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationCellular immunology
AuthorsFang Tan, Xianhe Li, Shiyu Liu +6 more
InstitutionThe Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University & The First People's Hospital of Xuzhou, Xuzhou 221112, Jiangsu Province, China.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedJul 29, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Ginger-derived exosome-like nanoparticles incorporated into hydrogel matrix for enhanced oral delivery of celastrol to alleviate ulcerative colitis.
The study describes a new oral delivery system designed to improve colon targeting and anti-inflammatory activity of celastrol, which could eventually lead to better drug options for ulcerative colitis if advanced to...
Extracellular Vesicles Derived from Elaeocarpus braceanus Alleviate DSS-Induced Ulcerative Colitis in Mice Through Multiple Pathways
This study describes a new plant-derived nanoparticle (EBDEVs) that reduced inflammation and improved colon health in a mouse model of ulcerative colitis and altered the gut microbiota — early evidence that may guide...
Celastrol ameliorates ulcerative colitis by inhibiting HSP90-mediated necroptosis of intestinal epithelial cells
The study suggests a new mechanism—blocking HSP90-mediated necroptosis of intestinal epithelial cells—that may reduce inflammation and tissue damage in ulcerative colitis, which could guide early drug-discovery efforts.